Literature DB >> 17593065

Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'.

F Pace1, M Tonini, S Pallotta, P Molteni, G B Porro.   

Abstract

BACKGROUND: Proton pump inhibitors (PPI) therapy 'on-demand' is often used as an alternative to continuous maintenance therapy in gastro-oesophageal reflux disease (GERD). AIM: We conducted a systematic review with the specific objectives to ascertain whether on-demand PPI therapy was effective in preventing symptomatic relapse and to assess the relative efficacy of on-demand vs. continuous PPI maintenance strategy.
METHODS: Randomized-controlled clinical trials comparing on-demand PPI vs. placebo or on-demand vs. continuous PPI therapy in GERD patients were identified by searching the Medline database and the Cochrane Controlled Trials Register.
RESULTS: Seventeen studies were found which met inclusion criteria. Out of the 17 studies: five investigated exclusively patients with non-erosive reflux disease (NERD), four patients with NERD and mild oesophagitis, two patients with erosive oesophagitis only, and two patients with uninvestigated GERD symptoms, respectively. Four further studies were not investigating the effectiveness of the therapies but primarily pharmacoeconomic or quality of life parameters.
CONCLUSIONS: On the basis of the analysis of 17 studies, we can conclude that on-demand therapy with currently available PPI appears to be effective in the long-term management of patients with NERD or mild and uninvestigated forms of GERD, but not in patients with (severe) erosive oesophagitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593065     DOI: 10.1111/j.1365-2036.2007.03381.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  28 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

Review 2.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Maintenance therapy of gastroesophageal reflux disease.

Authors:  Akihito Nagahara; Mariko Hojo; Daisuke Asaoka; Sumio Watanabe
Journal:  Clin J Gastroenterol       Date:  2010-02-19

4.  Long-Term PPI Use: Balancing Potential Harms and Documented Benefits.

Authors:  Loren Laine; Anil Nagar
Journal:  Am J Gastroenterol       Date:  2016-04-26       Impact factor: 10.864

5.  The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.

Authors:  Muhammad Ali Khan; Colin W Howden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

Review 6.  Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review.

Authors:  Sander Jo van Zanten; Catherine Henderson; Nesta Hughes
Journal:  Can J Gastroenterol       Date:  2012-04       Impact factor: 3.522

Review 7.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Strategies for Effective Discontinuation of Proton Pump Inhibitors.

Authors:  Judith Kim; John W Blackett; Daniela Jodorkovsky
Journal:  Curr Gastroenterol Rep       Date:  2018-05-16

9.  Gastroesophageal reflux disease: medical or surgical treatment?

Authors:  Theodore Liakakos; George Karamanolis; Paul Patapis; Evangelos P Misiakos
Journal:  Gastroenterol Res Pract       Date:  2009-12-31       Impact factor: 2.260

10.  Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial.

Authors:  Per G Farup; Mathis Heibert; Victor Høeg
Journal:  BMC Complement Altern Med       Date:  2009-02-24       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.